Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term WP-1303 ophthalmic solution in POAG or ocular hypertension
jRCT2080224167Phase 3Completed
- Sponsor
- Wakamoto Pharmaceutical
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ripasudil + brimonidine in open-angle glaucoma (OAG), normal tension glaucoma (NTG), pseudoexfoliation glaucoma (PXG) and 2 more, sponsored by Wakamoto Pharmaceutical. Started Dec 2018; status: completed.
02
Drugs
ripasudil + brimonidine
03
Conditions
open-angle glaucoma (OAG)normal tension glaucoma (NTG)pseudoexfoliation glaucoma (PXG)pigmentary glaucoma (PG)ocular hypertension
Beyond the preview
Go deeper on jRCT2080224167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224167.